Investors

IR tagline

Corporate Profile

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate is BIO89-100, which is being developed for the treatment of NASH. Currently in a proof of concept Phase 1b/2a clinical trial, BIO89-100 is a specifically engineered glycoPEGylated analog of FGF21. 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Data Provided by Refinitiv. Minimum 15 minutes delayed.